"It's about having the choice": Stakeholder perceptions of population-based genetic carrier screening for fragile X syndrome

American Journal of Medical Genetics, Part A

Volumn 161, Issue 1, 2013, Pages 48-58

  Archibald, Alison D ^a,b,c   Hickerton, Chriselle L ^a   Jaques, Alice M ^a   Wake, Samantha ^a,b,c   Cohen, Jonathan ^a,d,e   Metcalfe, Sylvia A ^a,b  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c VICTORIAN CLINICAL GENETICS SERVICES   (Australia)

^d Fragile X Alliance Inc (Clinic and Resource Centre)   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Attitudes; Carrier screening; Community genetics; Fragile X syndrome; Genetic counseling; Population screening; Qualitative research

Indexed keywords

ADOLESCENT; ARTICLE; ATAXIA; EMOTIONALITY; FAMILY DECISION MAKING; FAMILY PLANNING; FEMALE; FRAGILE X SYNDROME; GENETIC COUNSELING; GENETIC SCREENING; HEALTH PERSONNEL ATTITUDE; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREGNANCY TERMINATION; PRENATAL SCREENING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SOCIAL ASPECT; TREMOR;

ATTITUDE TO HEALTH; CHILD, PRESCHOOL; CHOICE BEHAVIOR; DECISION MAKING; FEMALE; FOCUS GROUPS; FRAGILE X SYNDROME; GENETIC TESTING; GENETICS, POPULATION; HETEROZYGOTE; HUMANS; MALE; PERCEPTION; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84871704394     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.35674     Document Type: Article

References (55)

1. Acharya K, Ross LF. 2009. Fragile X screening: Attitudes of genetic health professionals. Am J Med Genet A 149A:626-632.
2. Anido A, Carlson LM, Sherman SL. 2007. Attitudes toward fragile X mutation carrier testing from women identified in a general population survey. J Genet Couns 16:97-104.
3. Anido A, Carlson LM, Taft L, Sherman SL. 2005. Women's attitudes toward testing for fragile X carrier status: A qualitative analysis. J Genet Couns 14:295-306.
4. Archibald AD, Jaques AM, Wake S, Collins VR, Cohen J, Metcalfe SA. 2009. "It's Something I Need to Consider": Decisions about carrier screening for fragile X syndrome in a population of non-pregnant women. Am J Med Genet A 149A:2731-2738.
5. Archibald AD, McClaren BJ. 2012. Perceived relevance of genetic carrier screening: Observations of the role of health-related life experiences and stage of life in decision making. J Community Genet 3:47-54.
6. Bailey DB Jr, Skinner D, Sparkman KL. 2003. discovering fragile X syndrome: Family experiences and perceptions. Pediatrics 111:407-416.
7. Berkenstadt M, Ries-Levavi L, Cuckle H, Peleg L, Barkai G. 2007. preconceptional and prenatal screening for fragile X syndrome: Experience with 40, 000 tests. Prenat Diagn 27:991-994.
8. Bodega B, Bione S, Dalpra L, Toniolo D, Ornaghi F, Vegetti W, Ginelli E, Marozzi A. 2006. influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod 21:952-957.
9. Braun V, Clarke V. 2006. Using thematic analysis in psychology. Qual Res Psychol 3:77-101.
10. Bretherick KL, Fluker MR, Robinson WP. 2005. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet 117:376-382.
11. Charmaz K. 2006. Constructing grounded theory: A practical guide through qualitative analysis. Los Angeles: Sage.
12. Coffey SM, Cook K, Tartaglia N, Tassone F, Nguyen DV, Pan R, Bronsky HE, Yuhas J, Borodyanskaya M, Grigsby J, Doerflinger M, Hagerman PJ, Hagerman RJ. 2008. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 146A:1009-1016.
13. Cronister A, DiMaio M, Mahoney MJ, Donnenfeld AE, Hallam S. 2005. Fragile X syndrome carrier screening in the prenatal genetic counseling setting. Genet Med 7:246-250.
14. Dombrowski C, Levesque S, Morel ML, Rouillard P, Morgan K, Rousseau F. 2002. Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: Loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet 11:371-378.
15. Fanos JH, Spangner KA, Musci TJ. 2006. Attitudes toward prenatal screening and testing for fragile X. Genet Med 8:129-133.
16. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. 2009. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn 11:324-329.
17. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick RG Jr, Warren ST., et al. 1991. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell 67:1047-1058.
18. Gates EA. 2004. Communicating risk in prenatal genetic testing. J Midwifery Womens Health 49:220-227.
19. Geva E, Yaron Y, Shomrat R, Ben-Yehuda A, Zabari S, Peretz H, Naiman T, Yeger H, Orr-Urtreger A. 2000. The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families. Genet Test 4:289-292.
20. Glaser BG, Strauss AL. 1967. The discovery of grounded theory: Strategies for qualitative research. New York: Aldine De Gruyter.
21. Godard B, ten Kate L, Evers-Kiebooms G, Ayme S. 2003. Population genetic screening programmes: Principles, techniques, practices, and policies. Eur J Hum Genet 11:S49-S87.
22. Hagerman RJ. 2002. The Physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: Diagnosis, treatment and research, 3rd edition. Baltimore: The Johns Hopkins University Press. pp 3-119.
23. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ. 2001. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57:127-130.
24. Hallowell N, Richards MP. 1997. Understanding life's lottery: An evaluation of studies of genetic risk awareness. J Health Psychol 2:31-43.
25. Hantash FM, Goos DM, Crossley B, Anderson B, Zhang K, Sun W, Strom CM. 2011. Fmr1 premutation carrier frequency in patients undergoing routine population-based carrier screening: Insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. Genet Med 13:39-45.
26. Hill MK, Archibald AD, Cohen J, Metcalfe SA. 2010. A systematic review of population screening for fragile X syndrome. Genet Med 12:396-410.
27. Hollingsworth B, Harris A. 2005. Economic evaluation of prenatal population screening for fragile X syndrome. Community Genet 8:68-72.
28. Huang KF, Chen WY, Tsai YC, Lin CC, Chen SH, Tseng CY, Tzeng CC. 2003. Original article pilot screening for fragile X carrier in pregnant women of Southern Taiwan. JCMA 66:204-209.
29. Jacquemont S, Hagerman RJ, Leehey MA, Hall DA, Levine RA, Brunberg JA, Zhang L, Jardini T, Gane LW, Harris SW, Herman K, Grigsby J, Greco CM, Berry-Kravis E, Tassone F, Hagerman PJ. 2004. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 291:460-469.
30. Lewis C, Skirton H, Jones R. 2011. Can we make assumptions about the psychosocial impact of living as a carrier, based on studies assessing the effects of carrier testing? J Genet Couns 20:80-97.
31. Loesch DZ, Godler DE, Khaniani M, Gould E, Gehling F, Dissanayake C, Burgess T, Tassone F, Huggins R, Slater H, Choo KH. 2009b. Linking the FMR1 alleles with small CGG expansions with neurodevelopmental disorders: Preliminary data suggest an involvement of epigenetic mechanisms. Am J Med Genet A 149A:2306-2310.
32. Loesch DZ, Khaniani MS, Slater HR, Rubio JP, Bui QM, Kotschet K, D'Souza W, Venn A, Kalitsis P, Choo AK, Burgess T, Johnson L, Evans A, Horne M. 2009a. Small CGG repeat expansion alleles of FMR1 gene are associated with parkinsonism. Clin Genet 76:471-476.
33. McConkie-Rosell A, Abrams L, Finucane B, Cronister A, Gane LW, Coffey SM, Sherman S, Nelson LM, Berry-Kravis E, Hessl D, Chiu S, Street N, Vatave A, Hagerman RJ. 2007. Recommendations from multi-disciplinary focus groups on cascade testing and genetic counseling for fragile X-associated disorders. J Genet Couns 16:593-606.
34. McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ. 2005. Genetic counseling for fragile X syndrome: Updated recommendations of the national society of genetic counselors. J Genet Couns 14:249-270.
35. McConkie-Rosell A, Spiridigliozzi GA, Iafolla T, Tarleton J, Lachiewicz AM. 1997. Carrier testing in the fragile X syndrome: Attitudes and opinions of obligate carriers. Am J Med Genet 68:62-69.
36. McConkie-Rosell A, Spiridigliozzi GA, Sullivan JA, Dawson DV, Lachiewicz AM. 2001. Longitudinal study of the carrier testing process for fragile X syndrome: Perceptions and coping. Am J Med Genet 98:37-45.
37. Metcalfe S. 2011. Carrier screening in preconception consultation in primary care. J Community Genet 3:193-203.
38. Metcalfe S, Jaques A, Archibald A, Burgess T, Collins V, Henry A, McNamee K, Sheffield L, Slater H, Wake S, Cohen J. 2008. A model for offering carrier screening for fragile X syndrome to nonpregnant women: Results from a pilot study. Genet Med 10:525-535.
39. Musci TJ, Caughey AB. 2005. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 192:1905-1912 ; discussion 1912-1905.
40. Nolin SL, Brown WT, Glicksman A, Houck GE Jr, Gargano AD, Sullivan A, Biancalana V, Brondum-Nielsen K, Hjalgrim H, Holinski-Feder E, Kooy F, Longshore J, Macpherson J, Mandel JL, Matthijs G, Rousseau F, Steinbach P, Vaisanen ML, von Koskull H, Sherman SL. 2003. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 72:454-464.
41. Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boue J, Bertheas M, Mandel J. 1991. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252:1097-1102.
42. Pastore LM, Karns LB, Pinkerton JV, Silverman LM, Williams CD, Camp TR. 2006. Acceptance of Fragile X Premutation Genetic Screening in Women with Ovarian Dysfunction. Am J Obstet Gynecol 194:738-743.
43. Pastore LM, Morris WL, Karns LB. 2008. Emotional reaction to fragile X premutation carrier tests among infertile women. J Genet Couns 17:84-91.
44. Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, Barkai G. 2000. Screening for fragile X syndrome in women of reproductive age. Prenatal Diag 20:611-614.
45. Rice PL, Ezzy D. 1999. Qualitative research methods: A health focus. New York: Oxford Univeristy Press.
46. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, Xuncla M, Badenas C, Kulisevsky J, Gomez B, Mila M. 2009. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet 17:1359-1362.
47. Ryynanen M, Heinonen S, Makkonen M, Kajanoja E, Mannermaa A, Pertti K. 1999. Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies. Eur J Hum Genet 7:212-216.
48. Sherman S, Pletcher BA, Driscoll DA. 2005. Fragile X syndrome: Diagnostic and carrier testing. Genet Med 7:584-587.
49. Skinner D, Sparkman KL, Bailey DB Jr. 2003. Screening for Fragile X Syndrome: Parent Attitudes and Perspectives. Genet Med 5:378-384.
50. Spence WC, Black SH, Fallon L, Maddalena A, Cummings E, Menapace-Drew G, Bick DP, Levinson G, Schulman JD, Howard-Peebles PN. 1996. Molecular fragile X screening in normal populations. Am J Med Genet 64:181-183.
51. Toledano-Alhadef H, Basel-Vanagaite L, Magal N, Davidov B, Ehrlich S, Drasinover V, Taub E, Halpern GJ, Ginott N, Shohat M. 2001. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 69:351-360.
52. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, Eussen BE, van Ommer GJB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST. 1991. Identification of a gene (FMR1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-914.
53. Wildhagen MF, van Os TA, Polder JJ, ten Kate LP, Habbema JD. 1998. Explorative study of costs, effects and savings of screening for female fragile x premutation and full mutation carriers in the general population. Community Genet 1:36-47.
54. Wittenberger MD, Hagerman RJ, Sherman SL, McConkie-Rosell A, Welt CK, Rebar RW, Corrigan EC, Simpson JL, Nelson LM. 2007. The FMR1 premutation and reproduction. Fertil Steril 87:456-465.
55. Yu S, Pritchard M, Kremer E, Lynch M, Nancarrow J, Baker E, Holman K, Mulley J, Warren S, Schlessinger D, Sutherland GR, Richards RI. 1991. Fragile X genotype characterized by an unstable region of DNA. Science 252:1179-1181.